We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the microtubular network. Microtubules are the largest cytoskeletal elements and provide structural support to human cells in addition to accommodating the intracellular trafficking system employed to deliver essential cargoes. Numerous human pathologies have specifically been linked to dysregulation of microtubule properties and this is where we act.
The company roots on a unique platform technology providing chemical versatility to develop first-in-class compounds that serve drug development programs. Employing a knowledge-based view, MT-act develops drug candidates to correct microtubule dysfunctions. The choice of the targeted mode of action is highly differentiated.
Origin and Innovation
Based on breakthrough discoveries, proprietary technologies and unique expertise, MT-act screens, validates and isolates the best compounds with a unique microtubule-focused mode-of-action (MoA). MT-act pre-clinically develops compounds to act and restore microtubule function (MT).
Unique approach and new mechanism of action (MoA). Proprietary biochemical assay for compound screening.
First-in-class compounds that target a microtubule-focused mechanism of action (MoA).
Unmet medical need
Glaucoma is an eye disease notorious as the world’s leading cause of irreversible blindness. Affecting 20 million people in Europe and the US.
Trained and experienced team of biochemists, molecular and cellular biologists.